[
    {
        "molecule_name": "3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[1-(4-fluorophenyl)-3-hydroxypropyl]-1,3-thiazolidine-2-carboxamide",
        "protein_target_name": "human FP-R",
        "binding_metric": "Ki",
        "value": "6",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. Compound II, previously described in US 8,415,480, is an antagonist of the prostaglandin F receptor, as this compound exhibits an inhibition constant (Ki) of 6 nM for human FP-R as determined by competitive radioligand binding assays.\n2. It has been discovered that compound I is an inhibitor of the prostaglandin F receptor, as compound I inhibits human FP-R with a Ki of 1 nM."
    },
    {
        "molecule_name": "Atosiban",
        "protein_target_name": "human FP-R",
        "binding_metric": "Ki",
        "value": "1",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. Compound II, previously described in US 8,415,480, is an antagonist of the prostaglandin F receptor, as this compound exhibits an inhibition constant (Ki) of 6 nM for human FP-R as determined by competitive radioligand binding assays.\n2. It has been discovered that compound I is an inhibitor of the prostaglandin F receptor, as compound I inhibits human FP-R with a Ki of 1 nM."
    }
]